Renaissance Capital logo

Precision BioSciences Priced, Nasdaq: DTIL

Early-stage biotech developing off-the-shelf CAR T cell cancer therapies.

Industry: Health Care

First Day Return: +9.0%

Industry: Health Care

We are a genome editing company dedicated to improving life through our groundbreaking proprietary genome editing platform, ARCUS. We leverage ARCUS in the development of our product candidates, which are designed to treat human diseases and create healthy and sustainable food and agricultural solutions. We believe the versatility and breadth of ARCUS support our ability to develop products across the spectrum of biotechnology. We are actively developing product candidates in three innovative and high value areas where we believe our technology has the potential to overcome the limitations of other genome editing technologies: allogeneic CAR T immunotherapy, in vivo gene correction, and food. The U.S. Food and Drug Administration, or FDA, recently accepted our investigational new drug, or IND, application for our first gene-edited allogeneic CAR T cell candidate targeting CD19 and we expect to commence a Phase 1/2a clinical trial in patients with acute lymphoblastic leukemia and non-hodgkin lymphoma in the first half of 2019. We believe this trial will be the first clinical investigation of an allogeneic CAR T therapy for non-hodgkin lymphoma. We believe our proprietary, one-step engineering process for producing allogeneic CAR T cells at large scale in a cost-effective manner will enable us to overcome the fundamental challenges of manufacturing that have limited the CAR T field to date.
more less
IPO Data
IPO File Date 03/01/2019
Offer Price $16.00
Price Range $15.00 - $17.00
Offer Shares (mm) 7.9
Deal Size ($mm) $126
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 03/27/2019
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $126
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Durham, NC, United States
Founded 2006
Employees at IPO 127
Website www.precisionbiosciences.com

Precision BioSciences (DTIL) Performance